LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer

Xu, Jian; Wang, Jie; He, Zhiwei; Chen, Peng; Jiang, Xueyi; Chen, Yankun; Liu, Xinyuan; Jiang, Jianxin

doi:10.1038/s41419-021-03921-3

Cited by 34 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study of breast cancer by Yan et al, it was found that CERS6-AS1 may improve the proliferation of breast cancer through miR-125a-5p, and the expression of CERS6-AS1 is up-regulated in breast cancer tissues [ 28 ]. Subsequently, CERS6-AS1 was also confirmed to show high expression levels in different pancreatic cancer cell lines [ 25 ]. According to the clinical characteristics of gastric cancer patients and Cox analysis, it can be inferred that lncRNA CERS6-AS1 may be a prognostic factor of gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

“…When the level of CERS6-AS1 decreased, the expression of miR-567 was up-regulated. Similarly, the study of Xu et al about the mechanism of CERS6-AS1 on pancreatic cancer concluded that CERS6-AS1 also negatively adjusted miR-217 [ 25 ]. The literature shows that lncRNA CERS6-AS1 is used in the research and analysis of a variety of cancer processes, such as hepatocellular carcinoma [ 35 ], pancreatic cancer [ 25 , 36 ], breast cancer [ 28 ], and most of them are related to the poor prognosis of tumors by targeting miRNAs.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, the study of Xu et al about the mechanism of CERS6-AS1 on pancreatic cancer concluded that CERS6-AS1 also negatively adjusted miR-217 [ 25 ]. The literature shows that lncRNA CERS6-AS1 is used in the research and analysis of a variety of cancer processes, such as hepatocellular carcinoma [ 35 ], pancreatic cancer [ 25 , 36 ], breast cancer [ 28 ], and most of them are related to the poor prognosis of tumors by targeting miRNAs. In other words, CERS6-AS1 has been verified herein to play a role in the gene regulation of miR-567, and might be used as a potential biomarker for prognosis assessment.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Long non-coding RNA CERS6-AS1 plays a prognostic role in promoting the progression of gastric cancer

Jiang

Luo

et al. 2021

Bioengineered

View full text Add to dashboard Cite

This study aims to investigate the potential clinical function of long non-coding RNA CERS6-AS1 (lncRNA CERS6-AS1) integrated miR-567 in gastric cancer. The expression of CERS6-AS1 in gastric cancer tissues was detected through RT-qPCR in contrast to the normal tissues. The correlation between the expression of lncRNA CERS6-AS1 and the characteristics of clinical data was analyzed. Kaplan-Meier curve was used to assess the survival analysis, while Cox proportional hazards model multivariate analysis was performed to evaluate the prognostic risk factors of gastric cancer to verify the prognostic possibility of CERS6-AS1. The expression of CERS6-AS1 in different gastric cancer cells was detected, being the development of gastric cancer cells after knockdown CERS6-AS1 studied using CCK-8, Transwell migration, and invasion detection methods. The targeting effect and interaction between CERS6-AS1 and miR-567 through biological analysis and luciferase activity detection. The expression of lncRNA CERS6-AS1 was elevated in gastric cancer tissues and cells. The results of this study demonstrate that the condition of gastric cancer patients was related to the expression of CERS6-AS1, and therefore CERS6-AS1 might be a prognostic factor for the progression of gastric cancer. In addition, the ability of gastric cancer cells to proliferate, migrate and invade could be reduced by knockdown CERS6-AS1. After CERS6-AS1 knockdown, the expression level of miR-567 in gastric cancer tissues decreased, while the expression level of miR-567 increased. In conclusion, lncRNA CERS6-AS1 might promote the progression of gastric cancer and had the potential as a prognostic marker of gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long non-coding RNA CERS6-AS1 plays a prognostic role in promoting the progression of gastric cancer

Jiang

Luo

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…Utilization of a miRNA-based cancer treatment is not yet applied because a miRNA might have different targets in various cell types which are not characterized, thus leading to off-target effects. Identification of a ncRNA's mechanism in cancer alongside with its associated genetic variation remains a priority, which can be tackled by utilizing novel, RNA-centric methods [352][353][354]. Therefore, focusing our efforts on understanding and uncovering the non-coding portion of cancer variability not only can accommodate early diagnosis of malignancies but can also lead to the development of personalized therapeutic strategies.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine

Lange

Begolli

Giakountis

2021

ncRNA

View full text Add to dashboard Cite

The cancer genome is characterized by extensive variability, in the form of Single Nucleotide Polymorphisms (SNPs) or structural variations such as Copy Number Alterations (CNAs) across wider genomic areas. At the molecular level, most SNPs and/or CNAs reside in non-coding sequences, ultimately affecting the regulation of oncogenes and/or tumor-suppressors in a cancer-specific manner. Notably, inherited non-coding variants can predispose for cancer decades prior to disease onset. Furthermore, accumulation of additional non-coding driver mutations during progression of the disease, gives rise to genomic instability, acting as the driving force of neoplastic development and malignant evolution. Therefore, detection and characterization of such mutations can improve risk assessment for healthy carriers and expand the diagnostic and therapeutic toolbox for the patient. This review focuses on functional variants that reside in transcribed or not transcribed non-coding regions of the cancer genome and presents a collection of appropriate state-of-the-art methodologies to study them.

show abstract

“…lncRNAs control gene expression at different transcriptional levels via distinctly different mechanisms ( 12 ). Aberrant expression of lncRNAs has been proved in nearly all types of human cancer, such as bladder ( 13 ), cervical ( 14 ), gastric ( 15 ) and pancreatic cancers ( 16 ). Several lncRNAs have been found to be increased or decreased in NSCLC and have been identified as important indicators of cancer progression, such as WTA-AS ( 17 ), B4GALT1-AS1 ( 18 ) and CCAT1 ( 19 ).…”

Section: Introductionmentioning

confidence: 99%

Long non‑coding RNA LINC01748 exerts carcinogenic effects in non‑small cell lung cancer cell lines by regulating the microRNA‑520a‑5p/HMGA1 axis

Tan

et al. 2021

Int J Mol Med

View full text Add to dashboard Cite

The important functions of long non-coding RNAs in the malignancy of non-small cell lung cancer (NSCLC) has been increasingly highlighted. However, whether LINC01748 functions in a crucial regulatory role still requires further research. The aim of the present study was to investigate the biological roles of LINC01748 in NSCLC. Furthermore, different experiments were utilized to investigate the mechanism of action of LINC01748 in 2 NSCLC cell lines. Reverse transcription-quantitative PCR was used to measure mRNA expression levels. Cell Counting Kit-8 assay, flow cytometry analysis and Transwell and Matrigel assays were also used to analyze, cell viability, apoptosis, and migration and invasion, respectively. A tumor xenograft model was used for in vivo experiments. RNA immunoprecipitation experiments, luciferase reporter assays and rescue experiments were used to investigate the mechanisms involved. Data from The Cancer Genome Atlas dataset and patients recruited into the present study showed that LINC01748 was overexpressed in NSCLC. Patients with high LINC01748 mRNA expression level had shorter overall survival rate compared with that in patients with low LINC01748 mRNA expression level. Then, knockdown of LINC01748 mRNA expression level reduced cell proliferation, migration and invasion, but increased cell apoptosis in vitro . Knockdown of LINC01748 also reduced tumor growth in vivo . Mechanistically, LINC01748 could act as a competing endogenous (ce)RNA to sponge microRNA(miR)-520a-5p, to increase the expression level of the target gene, high mobility group AT-hook 1 (HMGA1) in the NSCLC cell lines. Furthermore, rescue experiments illustrated that the functions exerted by LINC01748 knockdown were negated by miR-520a-5p inhibition or HMGA1 overexpression. In summary, LINC01748 acted as a ceRNA by sponging miR-520a-5p, leading to HMGA1 overexpression, thus increasing the aggressiveness of the NSCLC cells. Accordingly, targeting the LINC01748/miR-520a-5p/HMGA1 pathway may benefit NSCLC therapy.

show abstract

LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer

Cited by 34 publications

References 26 publications

Long non-coding RNA CERS6-AS1 plays a prognostic role in promoting the progression of gastric cancer

Long non-coding RNA CERS6-AS1 plays a prognostic role in promoting the progression of gastric cancer

Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine

Long non‑coding RNA LINC01748 exerts carcinogenic effects in non‑small cell lung cancer cell lines by regulating the microRNA‑520a‑5p/HMGA1 axis

Contact Info

Product

Resources

About